Cardiogenic shock diagnostic criteria
|
Cardiogenic Shock Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiogenic shock diagnostic criteria On the Web |
|
American Roentgen Ray Society Images of Cardiogenic shock diagnostic criteria |
|
Risk calculators and risk factors for Cardiogenic shock diagnostic criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: James Nasr[2]
Cardiogenic shock diagnostic criteria
Overview
Cardiogenic shock is diagnosed when a primary cardiac disorder causes sustained systemic tissue hypoperfusion, with or without hypotension. Contemporary diagnostic frameworks emphasize integration of clinical findings, biochemical evidence of malperfusion, echocardiography, and, when needed, invasive hemodynamic assessment.[1][2][3]
The diagnosis should not be delayed until frank hypotension develops. Normotensive cardiogenic shock is recognized when there is evidence of organ hypoperfusion despite systolic blood pressure ≥90 mm Hg and no requirement for vasoactive or mechanical support to maintain blood pressure.[1][2]
Standardized SHARC definition
The Shock Academic Research Consortium (SHARC) defines cardiogenic shock as a cardiac disorder resulting in clinical and biochemical evidence of sustained tissue hypoperfusion.[1] Core diagnostic elements include:
- A primary cardiac disorder causing inadequate systemic perfusion
- Sustained hypotension, commonly systolic blood pressure <90 mm Hg for at least 30 minutes, a decrease in systolic blood pressure >30 mm Hg from baseline, or the need for inotropes, vasopressors, or mechanical circulatory support to maintain systolic blood pressure ≥90 mm Hg
- Evidence of systemic hypoperfusion, including cold or clammy extremities, altered mental status, oliguria, elevated lactate, acute kidney injury, or hepatic injury
- Exclusion or recognition of additional non-cardiac contributors, such as septic shock, hypovolemic shock, or obstructive shock
Hemodynamic thresholds used in the SHARC framework include cardiac index ≤2.2 L/min/m² and systemic vascular resistance index >2200 dynes·sec/cm-5/m² when advanced hemodynamic data are available.[1]
SUSPECT CS bedside diagnostic framework
The 2025 ACC Expert Consensus Statement proposes the SUSPECT CS mnemonic as a structured bedside approach to identify cardiogenic shock using readily obtainable clinical, laboratory, and imaging data.[4]
| SUSPECT CS element | Diagnostic focus | Examples |
|---|---|---|
| Symptoms/Signs | Clinical evidence of low output, congestion, or malperfusion | Altered mental status, confusion, chest pain or pressure, cold and clammy extremities, rapid pulse, low pulse pressure, dyspnea |
| Urine output | Assess renal perfusion | Oliguria, anuria, or declining urine output |
| Sustained hypotension | Identify hypotensive and normotensive presentations | Systolic blood pressure <90 mm Hg for at least 30 minutes, >30 mm Hg decrease from baseline, or need for pharmacological or mechanical support to maintain systolic blood pressure >90 mm Hg |
| Perfusion | Confirm end-organ malperfusion | Lactic acid >2 mmol/L, ALT >200 U/L or >3 times the upper limit of normal, creatinine ≥2 times the upper limit of normal, metabolic acidosis, altered mentation, cold extremities |
| ECG/Echocardiogram | Identify ischemic or arrhythmic cause and confirm cardiac dysfunction | Acute ischemia on electrocardiogram, sonographic evidence of regional wall motion abnormality, LV or RV dilation, systolic dysfunction, or acute valvular pathology |
| Congestion | Determine ventricular involvement | Physical or hemodynamic evidence of congestion; LV-dominant, RV-dominant, or biventricular involvement |
| Triage | Determine severity and need for escalation | SCAI stage assignment, shock team activation, or transfer to a higher level of care |
SCAI shock staging
The SCAI shock classification stages cardiogenic shock severity from at-risk to extremis and provides a shared language for clinical communication, risk stratification, and serial reassessment.[5][6][7]
| SCAI stage | Clinical definition | Typical diagnostic features |
|---|---|---|
| Stage A: At risk | Patient at risk for cardiogenic shock but without hypotension or hypoperfusion | Large myocardial infarction, acute heart failure, myocarditis, severe valvular disease, or post-cardiotomy state with preserved perfusion |
| Stage B: Beginning shock / preshock | Relative or absolute hypotension without clear clinical hypoperfusion by the original SCAI descriptors | Systolic blood pressure <90 mm Hg, mean arterial pressure 50-65 mm Hg, or >30 mm Hg fall from baseline; original SCAI descriptors include normal mentation, preserved urine output, and normal lactate |
| Stage C: Classic cardiogenic shock | Hypoperfusion requiring initial intervention | Hypotension plus clinical or biochemical hypoperfusion; may require one vasoactive drug or one mechanical circulatory support device |
| Stage D: Deteriorating shock | Worsening hypoperfusion despite initial therapy | Rising lactate, worsening renal or hepatic injury, escalating vasopressor or inotrope requirement, or need for additional mechanical circulatory support |
| Stage E: Extremis | Refractory shock or circulatory collapse | Cardiac arrest, ongoing cardiopulmonary resuscitation, recurrent ventricular tachycardia or ventricular fibrillation, severe acidosis, severe lactate elevation, or need for multiple drugs or support devices |
It should be noted that the Cardiogenic Shock Working Group operationalized criteria define stage B as having either isolated hypoperfusion, such as lactate 2-5 mmol/L or ALT 200-500 U/L, or hypotension, such as systolic blood pressure 60-90 mm Hg or mean arterial pressure 50-65 mm Hg, without drug or device therapy. This differs from the original SCAI descriptors, which list normal lactate for stage B, and reflects the difficulty of translating clinical staging into fixed laboratory thresholds.[7]
The key distinction between non-shock states and established shock is the presence of hypoperfusion. Hypoperfusion is more prognostically important than hypotension alone and should be actively sought even when blood pressure is preserved.[7]
Clinical diagnostic criteria
Clinical criteria should be interpreted as part of a syndrome rather than as isolated findings.
| Domain | Findings supporting cardiogenic shock |
|---|---|
| Blood pressure and pulse pressure | Systolic blood pressure <90 mm Hg, mean arterial pressure <65 mm Hg, >30 mm Hg fall from baseline, narrow pulse pressure, or need for vasopressor, inotrope, or mechanical circulatory support |
| Peripheral perfusion | Cool extremities, clammy skin, mottling, delayed capillary refill, weak pulses |
| Neurologic perfusion | Confusion, agitation, somnolence, altered mental status, coma after cardiac arrest |
| Renal perfusion | Oliguria, rising creatinine, worsening acute kidney injury |
| Pulmonary congestion | Dyspnea, hypoxemia, crackles, pulmonary edema, need for noninvasive or invasive ventilation |
| Venous congestion | Elevated jugular venous pressure, hepatomegaly, peripheral edema, elevated right-sided filling pressures |
| Etiology-specific clues | Chest pain, new murmur, arrhythmia, pericardial tamponade findings, right ventricular infarction, acute valvular catastrophe, myocarditis, or post-cardiotomy state |
Laboratory diagnostic criteria
Laboratory findings help confirm tissue hypoperfusion, identify organ injury, and monitor trajectory.
| Laboratory marker | Diagnostic role | Interpretation |
|---|---|---|
| Lactate | Core biochemical marker of hypoperfusion | Lactate >2 mmol/L supports systemic hypoperfusion; higher thresholds have been used in some trials, including >2.5 mmol/L in DanGer Shock and >3.0 mmol/L in ECLS-SHOCK.[3] |
| Arterial or venous blood gas | Assesses metabolic acidosis and severity of shock | Low pH and base deficit suggest advanced tissue hypoperfusion and impaired compensation. |
| Creatinine and urine output | Detects renal hypoperfusion and acute kidney injury | Rising creatinine or oliguria supports end-organ malperfusion. |
| Transaminases and bilirubin | Detects hepatic hypoperfusion or congestion | Marked aminotransferase elevation may indicate hypoxic hepatitis; milder elevation may reflect congestion or mixed injury. |
| Troponin | Identifies myocardial injury or acute coronary syndrome | Elevation supports ischemic or inflammatory myocardial injury but is not specific for cardiogenic shock. |
| BNP or NT-proBNP | Supports cardiac stretch and heart failure physiology | Elevated values may support heart failure-related shock but must be interpreted in clinical context. |
| Complete blood count and coagulation studies | Identifies anemia, bleeding, infection, thrombocytopenia, or coagulopathy | Important for identifying mixed shock, bleeding complications, or contraindications to invasive support. |
Hemodynamic diagnostic criteria
Invasive hemodynamic assessment with pulmonary artery catheterization is not required for the initial diagnosis in all patients, but it provides objective confirmation, distinguishes shock phenotypes, and guides escalation when the diagnosis or phenotype is uncertain.[4][2] The 2022 AHA/ACC/HFSA guideline assigns pulmonary artery catheter placement a class 2b, level of evidence C-LD recommendation in cardiogenic shock, stating that it may be considered to define hemodynamic subsets and appropriate management strategies.[8]
| Parameter | Typical abnormality in cardiogenic shock | Clinical use |
|---|---|---|
| Cardiac index | Usually low. The 2022 AHA/ACC/HFSA guideline lists cardiac index <2.2 L/min/m² in Table 23, while its explanatory text states ≤2.2 L/min/m²; both thresholds are used clinically as markers of low-output shock.[8] | Confirms low-output physiology when measured. |
| Pulmonary capillary wedge pressure | >15 mm Hg | Supports left-sided congestion or LV-dominant shock. |
| Central venous pressure / right atrial pressure | >15 mm Hg | Supports right-sided congestion, RV failure, or biventricular shock. |
| Cardiac power output | Reduced; commonly concerning when <0.6 W | Integrates flow and pressure; strong hemodynamic correlate of mortality. |
| Pulmonary artery pulsatility index | Low; prognostic cutoffs differ by context: ≤0.9 in acute myocardial infarction-related cardiogenic shock, <1.85 after LVAD implantation, and <1.0 in the 2022 AHA/ACC/HFSA guideline stage C table when central venous pressure is >10 mm Hg and pulmonary artery systolic pressure is >50 mm Hg.[4][9][8] | Helps identify RV-dominant or biventricular shock. |
| Central or mixed venous oxygen saturation | Reduced | Suggests impaired systemic oxygen delivery or increased extraction. |
| Systemic vascular resistance | May be elevated in pure cardiogenic shock or low/normal in mixed shock | Helps distinguish isolated cardiogenic shock from cardiogenic-distributive mixed shock. |
Hemodynamic phenotypes
| Phenotype | Typical findings | Diagnostic implication |
|---|---|---|
| LV-dominant shock | Low cardiac output with elevated pulmonary capillary wedge pressure or LV end-diastolic pressure; relatively lower right atrial pressure | Common in acute myocardial infarction-related LV failure and acute decompensated heart failure. |
| RV-dominant shock | Elevated right atrial pressure or central venous pressure >15 mm Hg, low pulmonary artery pulsatility index, relatively normal or less elevated pulmonary capillary wedge pressure, and elevated RA/PCWP ratio. Thresholds vary by context: the 2025 ACC statement uses >0.6 as a general adverse mortality threshold, the 2022 AHA mechanical circulatory support statement describes >0.86 in acute myocardial infarction and >0.63 after LVAD, and the 2022 AHA/ACC/HFSA stage C table uses CVP/PCWP >1.0.[4][9][8] | Suggests RV infarction, massive pulmonary embolism, RV failure after LVAD, pulmonary hypertension, or severe RV cardiomyopathy. |
| Biventricular shock | Elevated right- and left-sided filling pressures with low cardiac output | Associated with severe congestion, high organ-failure burden, and frequent need for advanced support. |
| Mixed cardiogenic-distributive shock | Cardiac dysfunction with low or inappropriately normal systemic vascular resistance | Suggests sepsis, inflammatory vasoplegia, post-cardiac arrest syndrome, or other distributive component. |
Role of echocardiography
Every patient with suspected cardiogenic shock should undergo transthoracic echocardiography or point-of-care cardiac ultrasound by an experienced clinician as part of the initial evaluation.[4][10]
Echocardiography helps:
- Confirm cardiac dysfunction as the cause of shock
- Assess LV and RV systolic function
- Estimate forward flow using LV outflow tract velocity-time integral
- Identify regional wall motion abnormalities suggesting acute coronary syndrome
- Detect mechanical complications of myocardial infarction, including ventricular septal defect, papillary muscle rupture, acute severe mitral regurgitation, and free wall rupture
- Identify acute valvular pathology
- Evaluate for pericardial effusion and cardiac tamponade
- Identify LV outflow tract obstruction
- Differentiate cardiogenic shock from obstructive, distributive, or hypovolemic shock
Normotensive cardiogenic shock
Normotensive cardiogenic shock is defined by evidence of organ hypoperfusion despite systolic blood pressure ≥90 mm Hg without the need for vasopressors, inotropes, or mechanical circulatory support.[1] It should be suspected when cardiac dysfunction is present with elevated lactate, renal or hepatic injury, altered mentation, cold extremities, oliguria, or prolonged capillary refill despite preserved blood pressure.
In the SHOCK trial registry, 4.6% of patients (49 of 1068) had nonhypotensive cardiogenic shock, defined as clinical evidence of peripheral hypoperfusion with systolic blood pressure >90 mm Hg without vasopressor support. In-hospital mortality was 43% in nonhypotensive cardiogenic shock, compared with 66% in classic hypotensive cardiogenic shock and 26% in hypotension alone without hypoperfusion.[11][12]
This entity is clinically important because isolated hypoperfusion carries higher mortality than isolated hypotension without hypoperfusion. Therefore, lactate and end-organ assessment should be performed when cardiogenic shock is suspected, even in the absence of hypotension.[7]
Mixed shock
Mixed shock is cardiogenic shock with an additional simultaneous non-cardiac contributor, such as distributive, hypovolemic, or obstructive shock.[1] Mixed shock should be suspected when cardiac dysfunction and hypoperfusion coexist with low systemic vascular resistance, fever, leukocytosis, bleeding, dehydration, tamponade, pulmonary embolism, or other non-cardiac shock physiology.
In the Critical Care Cardiology Trials Network registry applying SHARC definitions, 17% of patients meeting shock criteria had mixed shock, and mixed shock carried the highest in-hospital mortality among cardiogenic shock subtypes.[13]
Variation in trial definitions
Definitions of cardiogenic shock have varied across major randomized trials, limiting direct comparison of study populations and outcomes.[1][3]
| Trial | Key diagnostic features |
|---|---|
| SHOCK trial | Required clinical shock criteria plus invasive hemodynamic criteria, including cardiac index ≤2.2 L/min/m² and pulmonary capillary wedge pressure ≥15 mm Hg. |
| TRIUMPH | Included patients with acute myocardial infarction and refractory cardiogenic shock after opening of the infarct-related artery; trial definitions emphasized persistent hypotension and hypoperfusion after PCI. |
| IABP-SHOCK II | Required acute myocardial infarction with clinical pulmonary congestion and impaired end-organ perfusion, including lactate >2.0 mmol/L; invasive hemodynamic criteria were not required. |
| CULPRIT-SHOCK | Required acute myocardial infarction with multivessel coronary artery disease, identifiable culprit lesion, and clinical cardiogenic shock criteria. |
| ECLS-SHOCK | Used a higher lactate threshold than several prior trials, requiring lactate >3.0 mmol/L. |
| DanGer Shock | Required STEMI, systolic blood pressure <100 mm Hg or vasopressor support, lactate >2.5 mmol/L or reduced mixed venous oxygen saturation, and reduced LV systolic function; the trial population was therefore a selected infarct-related cardiogenic shock cohort rather than an all-comers cardiogenic shock population.[3][14] |
Common diagnostic pitfalls
- Waiting for hypotension before considering cardiogenic shock
- Failing to measure lactate or repeat lactate after initial resuscitation
- Treating cardiogenic shock as a static diagnosis rather than a dynamic syndrome requiring serial reassessment
- Assuming all cardiogenic shock is LV-dominant
- Missing RV-dominant, biventricular, or mixed shock physiology
- Applying a single trial definition as a universal diagnostic standard
- Interpreting elevated lactate without excluding sepsis, hypovolemia, severe hypoxemia, seizure, hepatic failure, or medication-related causes
Practical diagnostic approach
- Suspect cardiogenic shock in any patient with acute cardiac disease and hypotension, hypoperfusion, or unexplained organ dysfunction.
- Obtain immediate bedside assessment: vital signs, perfusion exam, mental status, urine output, electrocardiogram, lactate, blood gas, renal function, hepatic tests, cardiac biomarkers, and chest imaging when appropriate.
- Perform urgent transthoracic echocardiography or point-of-care cardiac ultrasound to confirm cardiac dysfunction and identify the shock phenotype.
- Assign an initial SCAI stage and reassess serially.
- Use invasive hemodynamic monitoring when the diagnosis is uncertain, shock is persistent or worsening, RV failure or mixed shock is suspected, or mechanical circulatory support is being considered.
- Reassess lactate, end-organ function, vasoactive needs, and SCAI stage after initial stabilization.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Waksman R, Pahuja M, van Diepen S; et al. (2023). "Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)". Circulation. 148 (14): 1113–1126. doi:10.1161/CIRCULATIONAHA.123.064527.
- ↑ 2.0 2.1 2.2 Lüsebrink E, Binzenhöfer L, Adamo M; et al. (2024). "Cardiogenic Shock". Lancet. 404 (10466): 2006–2020. doi:10.1016/S0140-6736(24)01818-X.
- ↑ 3.0 3.1 3.2 3.3 Thiele H, Hassager C (2026). "Cardiogenic Shock". The New England Journal of Medicine. 394 (1): 62–77. doi:10.1056/NEJMra2312086.
- ↑ 4.0 4.1 4.2 4.3 4.4 Sinha SS, Morrow DA, Kapur NK, Kataria R, Roswell RO (2025). "2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock". Journal of the American College of Cardiology. 85 (16): 1618–1641. doi:10.1016/j.jacc.2025.02.018.
- ↑ Baran DA, Grines CL, Bailey S; et al. (2019). "SCAI Clinical Expert Consensus Statement on the Classification of Cardiogenic Shock". Catheterization and Cardiovascular Interventions. 94 (1): 29–37. doi:10.1002/ccd.28329.
- ↑ Naidu SS, Baran DA, Jentzer JC; et al. (2022). "SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies". Journal of the American College of Cardiology. 79 (9): 933–946. doi:10.1016/j.jacc.2022.01.018.
- ↑ 7.0 7.1 7.2 7.3 Kapur NK, Kanwar M, Sinha SS; et al. (2022). "Criteria for Defining Stages of Cardiogenic Shock Severity". Journal of the American College of Cardiology. 80 (3): 185–198. doi:10.1016/j.jacc.2022.04.049.
- ↑ 8.0 8.1 8.2 8.3 Heidenreich PA, Bozkurt B, Aguilar D; et al. (2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure". Journal of the American College of Cardiology. 79 (17): e263–e421. doi:10.1016/j.jacc.2021.12.012.
- ↑ 9.0 9.1 Geller BJ, Sinha SS, Kapur NK; et al. (2022). "Escalating and De-Escalating Temporary Mechanical Circulatory Support in Cardiogenic Shock: A Scientific Statement From the American Heart Association". Circulation. 146 (6): e50–e68. doi:10.1161/CIR.0000000000001076.
- ↑ Balik M, Ng W, Dugar S (2026). "From Guideline to Precision: Echocardiography in the Management of Cardiogenic Shock". Current Opinion in Critical Care. doi:10.1097/MCC.0000000000001400.
- ↑ Samsky MD, Morrow DA, Proudfoot AG; et al. (2021). "Cardiogenic Shock After Acute Myocardial Infarction: A Review". JAMA. 326 (18): 1840–1850. doi:10.1001/jama.2021.18323.
- ↑ Menon V, Slater JN, White HD; et al. (2000). "Acute Myocardial Infarction Complicated by Systemic Hypoperfusion Without Hypotension: Report of the SHOCK Trial Registry". The American Journal of Medicine. 108 (5): 374–380. doi:10.1016/S0002-9343(00)00310-7.
- ↑ Berg DD, Bohula EA, Patel SM; et al. (2024). "Epidemiology of Cardiogenic Shock Using the Shock Academic Research Consortium (SHARC) Consensus Definitions". European Heart Journal: Acute Cardiovascular Care. 13 (10): 709–714. doi:10.1093/ehjacc/zuae098.
- ↑ Udesen NLJ, Beske RP, Hassager C; et al. (2025). "Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial". JAMA Cardiology. 10 (1): 9–16. doi:10.1001/jamacardio.2024.4197.